Stocktoria
Seres Therapeutics, Inc. MCRB
Seres Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789,000 | $0 | $0 | $7.1M | $144.9M | $33.2M | $34.5M | $28.3M | $32.1M | $21.8M |
| R&D expense | $49.1M | $64.6M | $117.6M | $109.7M | $141.9M | $90.6M | $80.1M | $96.0M | $89.5M | $82.0M |
| Operating income | -$94.0M | -$121.3M | -$195.1M | -$179.9M | -$64.5M | -$88.1M | -$71.9M | -$100.3M | -$91.4M | -$92.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $5.7M | $136,000 | -$113.7M | -$250.2M | -$65.6M | -$89.1M | -$70.3M | -$98.9M | -$89.4M | -$91.6M |
| EPS (diluted) | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 | $-1.12 | — | — | — | — |
| Operating cash flow | $1.1M | -$148.6M | -$117.4M | -$228.8M | $6.7M | -$93.6M | -$76.5M | -$62.9M | -$75.5M | $43.9M |
| Free cash flow | $865,000 | -$149.0M | -$125.3M | -$238.6M | -$2.9M | -$94.2M | -$77.5M | -$64.8M | -$80.2M | $22.4M |
| Cash & equivalents | $45.8M | $30.8M | $128.0M | $163.0M | $180.0M | $116.0M | $65.1M | $85.8M | $36.1M | $54.5M |
| Inventory | — | — | $29.6M | $0 | — | — | — | — | — | — |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M | $342.9M | $132.4M | $120.5M | $189.5M | $272.6M |
| Total liabilities | $94.0M | $126.0M | $403.5M | $338.0M | $223.4M | $168.2M | $180.8M | $168.5M | $128.8M | $140.0M |
| Shareholders' equity | $44.2M | $13.8M | -$44.9M | $10.8M | $131.5M | $174.8M | -$48.3M | -$48.0M | $60.7M | $132.6M |
Growth · year-over-year · Revenue CAGR -30.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -100.0% | -95.1% | +336.3% | -3.7% | +22.1% | -11.9% | +47.5% | — |
| Net income growth | +4088.2% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | — | — | — | — | -457.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.